Lantheus Holdings Inc (LNTH) said Tuesday that it entered a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction.
The transaction will consist of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments, the company said.
The acquisition has been approved by the boards of directors of both companies and is expected to close in the second half of 2025.
Lantheus reaffirmed its 2024 financial guidance. The company previously said it expects 2024 adjusted EPS of between $6.65 and $6.70 on revenue of between $1.51 billion and $1.52 billion.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。